Radiotherapy remains a fundamental treatment for prostate cancer, and recent developments in precision medicine and technological innovations have the potential to transform its efficacy and safety. With the emergence of next-generation technologies, there is a growing need to understand how these advances can be integrated into clinical practice effectively. Current challenges include improving the accuracy of radiation delivery, reducing associated toxicities, and customizing treatment based on individual patient profiles.

This Research Topic aims to delve into the innovative strategies and technologies that are setting the stage for a new era in prostate cancer radiotherapy. The focus will be on evaluating how these advancements can enhance precision, personalize treatment experiences, and ultimately improve patient outcomes.

To gather further insights in the realms of precision and personalization in prostate cancer radiotherapy, we welcome articles addressing, but not limited to, the following themes:
• Personalized Radiotherapy: including the use of genomic profiling, biomarkers, and predictive modeling to tailor treatment plans.
• Advanced Imaging Techniques: featuring innovations in the field of nuclear medicine, real-time adaptive radiotherapy, and motion management.
• Optimizing Hypofractionation: investigating the efficacy and safety of ultra-hypo fractionated regimens in prostate cancer management (including the setting of pelvic irradiation and the post-op setting).
• New Radiation Modalities: exploring the developments in proton therapy, heavy-ion therapy, and other adaptive radiotherapy techniques.
• Radiotherapy-Immune System Interactions: examining combinatory strategies with immunotherapy and radiosensitizers for enhanced therapeutic outcomes.

Types of articles sought include original research, reviews, and clinical studies to enrich our understanding of these transformative radiotherapy technologies.

Please note: case reports, manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.

Are you interested in contributing a manuscript to this Research Topic?

Next-Generation Radiotherapy for Prostate Cancer: Precision, Personalization, and Technological Advances